Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery

With numerous infections and fatalities, COVID-19 has wreaked havoc around the globe. The main protease (Mpro), which cleaves the polyprotein to form non-structural proteins, thereby helping in the replication of SARS-CoV-2, appears as an attractive target for antiviral therapeutics. As FDA-approved...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray, Abhik Kumar, Sen Gupta, Parth Sarthi, Panda, Saroj Kumar, Biswal, Satyaranjan, Bhattacharya, Uddipan, Rana, Malay Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714248/
https://www.ncbi.nlm.nih.gov/pubmed/34986429
http://dx.doi.org/10.1016/j.compbiomed.2021.105183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714248/
https://www.ncbi.nlm.nih.gov/pubmed/34986429
http://dx.doi.org/10.1016/j.compbiomed.2021.105183

Ejemplares similares